YU603A - N-oksidi kao prolekovi 4-fenil-piridinskih derivata koji su antagonsti nk1 receptora - Google Patents
N-oksidi kao prolekovi 4-fenil-piridinskih derivata koji su antagonsti nk1 receptoraInfo
- Publication number
- YU603A YU603A YU603A YUP603A YU603A YU 603 A YU603 A YU 603A YU 603 A YU603 A YU 603A YU P603 A YUP603 A YU P603A YU 603 A YU603 A YU 603A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- lower alkyl
- hydrogen
- phenyl
- independently
- oxides
- Prior art date
Links
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title abstract 2
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- 150000005362 4-phenylpyridines Chemical class 0.000 title 1
- 150000001204 N-oxides Chemical class 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- -1 cyclic tertiary amine Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Ovaj pronalazak se odnosi na jedinjenja opste formule I je R vodonik, nizi alkil, nizi alkoksi, halogen ili trifluormetil; R1 je vodonik ili halaogen; ili R i R1 mogu biti zajedno sa ugljenikovim atomima prstena za koji su prikaceni -CH=CH-CH=CH-; R2 i R2' su nezavisno jedan od drugog vodonik, halogen trifluormetil, nizi alkoksi ili cijano; ili R2 R2' mogu biti zajedno -CH=CH-CH?CH-, proizvoljno supstituisan sa jednim ili dva supstituenta izabrana od nizeg alkil ili nizeg alkoksi; R3, R3' su nezavisno jedan od drugog vodonik, nizi alkil ili cikloalkil; R4, R4' su nezavisno jedan od drugog -(CH2)mOR6 ili nizi alkil; ili R4 i R4' cine zajedno sa N-atomom za koji su prikaceni ciklicni tercijarni amin grupe II R5 je vodonik, hidroksi, nizi alkil, -nizi akoksi, -(CH2)mOH, -COOR3, -CON(R3)2, -N(R3)CO-nizi alkil ili -C(O)R3; R6 je vodonik, nizi alkil ili fenil; X je -(O)N(R6)-, -N(R6)C(O)-, -(CH2)mO-ili -O(CH2)m-; n je 0, 1, 2, 3 ili 4; i m je 1, 2 ili 3; i na njihove farmaceutski prihvatljive kisele adicione soli. Nadjeno je da ova jedinjenja mogu da se koriste kao prolekovi za tretiranje ili rpevenciju bolesti, povezanih sa NK1 receptorom.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00115287 | 2000-07-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| YU603A true YU603A (sh) | 2006-01-16 |
| RS50932B RS50932B (sr) | 2010-08-31 |
Family
ID=8169262
Country Status (38)
| Country | Link |
|---|---|
| US (4) | US6593472B2 (sh) |
| EP (1) | EP1303490B1 (sh) |
| JP (1) | JP3950044B2 (sh) |
| KR (1) | KR100501608B1 (sh) |
| CN (1) | CN1178917C (sh) |
| AR (1) | AR029717A1 (sh) |
| AT (1) | ATE400556T1 (sh) |
| AU (1) | AU7061901A (sh) |
| BR (1) | BRPI0112475B8 (sh) |
| CA (1) | CA2415890C (sh) |
| CY (1) | CY1108557T1 (sh) |
| CZ (1) | CZ303639B6 (sh) |
| DE (1) | DE60134749D1 (sh) |
| DK (1) | DK1303490T3 (sh) |
| EC (1) | ECSP034431A (sh) |
| EG (1) | EG24968A (sh) |
| ES (1) | ES2309075T3 (sh) |
| GT (1) | GT200100137A (sh) |
| HR (1) | HRP20030003B1 (sh) |
| HU (1) | HU230316B1 (sh) |
| IL (2) | IL153834A0 (sh) |
| JO (1) | JO2372B1 (sh) |
| MA (1) | MA26929A1 (sh) |
| ME (1) | ME01311B (sh) |
| MX (1) | MXPA03000366A (sh) |
| MY (1) | MY154976A (sh) |
| NO (1) | NO324700B1 (sh) |
| NZ (1) | NZ523273A (sh) |
| PA (1) | PA8522001A1 (sh) |
| PE (1) | PE20020272A1 (sh) |
| PL (1) | PL205207B1 (sh) |
| PT (1) | PT1303490E (sh) |
| RS (1) | RS50932B (sh) |
| RU (1) | RU2266284C2 (sh) |
| SI (1) | SI1303490T1 (sh) |
| UY (1) | UY26839A1 (sh) |
| WO (1) | WO2002006236A1 (sh) |
| ZA (1) | ZA200210207B (sh) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1103545B1 (en) * | 1999-11-29 | 2003-11-05 | F. Hoffmann-La Roche Ag | 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide |
| CN1178917C (zh) * | 2000-07-14 | 2004-12-08 | 弗·哈夫曼-拉罗切有限公司 | 作为nk1受体拮抗剂前药的4-苯基-吡啶衍生物的n-氧化物 |
| TWI287003B (en) * | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
| MXPA03009720A (es) * | 2001-04-23 | 2004-01-29 | Hoffmann La Roche | USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA. |
| HRP20070471T3 (hr) | 2003-07-03 | 2007-11-30 | F. Hoffmann - La Roche Ag | Dvojni nk1/nk3 antagonisti za liječenje shizofrenije |
| MX2007000198A (es) | 2004-07-06 | 2007-03-15 | Hoffmann La Roche | Proceso para la preparacion de derivados de carboxamida-piridina utilizados como intermediarios en la sintesis de antagonistas del receptor nk-1. |
| US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
| NZ560232A (en) | 2005-02-25 | 2010-11-26 | Hoffmann La Roche | Tablets with improved drug substance dispersibility |
| DK1863767T3 (da) * | 2005-03-23 | 2009-05-04 | Hoffmann La Roche | Metabolitter til NK-I-antagonister til emesis |
| JP2008280248A (ja) * | 2005-11-02 | 2008-11-20 | Eisai R & D Management Co Ltd | アルツハイマー型痴呆症治療薬塩酸ドネペジルのプロドラッグ |
| JP2010516731A (ja) | 2007-01-24 | 2010-05-20 | グラクソ グループ リミテッド | ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物 |
| GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| US8966414B2 (en) | 2009-05-29 | 2015-02-24 | Cypress Semiconductor Corporation | Implementing a circuit using an integrated circuit including parametric analog elements |
| US9858367B1 (en) | 2009-08-31 | 2018-01-02 | Cypress Semiconductor Corporation | Integrated circuit including parametric analog elements |
| CN106512010A (zh) | 2009-11-18 | 2017-03-22 | 赫尔辛医疗股份公司 | 用于治疗中枢介导的恶心及呕吐的组合物及方法 |
| EP2722045B1 (en) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
| EP2744497B1 (en) | 2011-10-18 | 2016-04-06 | Helsinn Healthcare SA | Therapeutic combinations of netupitant and palonosetron |
| US8426450B1 (en) * | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| DK3738434T3 (da) | 2011-12-28 | 2023-12-04 | Global Blood Therapeutics Inc | Mellemprodukter til opnåelse af substituerede benzaldehydforbindelser og fremgangsmåder til anvendelse deraf ved øgning af vævsoxygenering |
| WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| BR112015021982B1 (pt) * | 2013-03-15 | 2022-12-13 | Global Blood Therapeutics, Inc | Compostos e seus usos para a modulação de hemoglobina |
| AU2014237330A1 (en) | 2013-03-15 | 2015-09-17 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| KR102280614B1 (ko) | 2013-03-15 | 2021-07-21 | 글로벌 블러드 테라퓨틱스, 인크. | 헤모글로빈 조정을 위한 화합물 및 이의 용도 |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| BR112016009811A2 (pt) | 2013-11-08 | 2017-12-05 | Kissei Pharmaceutical | derivado de carboximetil piperidina |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| US10350098B2 (en) * | 2013-12-20 | 2019-07-16 | Volcano Corporation | Devices and methods for controlled endoluminal filter deployment |
| SI3102208T2 (sl) | 2014-02-07 | 2024-10-30 | Global Blood Therapeutics, Inc. | Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida |
| TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
| CN106588899B (zh) * | 2015-10-15 | 2019-11-15 | 江苏恒瑞医药股份有限公司 | 吡啶基取代的6-氧杂螺[4.5]癸烷类衍生物、其制备方法及其在医药上的应用 |
| US11020382B2 (en) | 2015-12-04 | 2021-06-01 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| AR108435A1 (es) | 2016-05-12 | 2018-08-22 | Global Blood Therapeutics Inc | Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído |
| TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| IL312486B2 (en) | 2017-04-10 | 2025-05-01 | Chase Therapeutics Corp | NK1 antagonist combination and method for treating synucleinopathies |
| IL271464B2 (en) | 2017-06-30 | 2024-08-01 | Chase Therapeutics Corp | NK-1 antagonist compositions and methods for use in the treatment of depression |
| EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
| WO2020163689A1 (en) | 2019-02-08 | 2020-08-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | 20-hete formation inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56106286A (en) | 1980-01-28 | 1981-08-24 | Nippon Musical Instruments Mfg | Electronic musical instrument |
| EP0103545A3 (en) | 1982-09-13 | 1984-10-03 | Arc Technologies Systems, Ltd. | Electrode for arc furnaces |
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| DE69434063D1 (de) | 1993-12-29 | 2004-11-11 | Merck Sharp & Dohme | Substituierte Morpholinderivate und ihre Verwendung als therapeutische Mittel |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| DE19627431A1 (de) * | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
| AR008789A1 (es) * | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
| EP1157005B1 (en) * | 1999-02-24 | 2004-10-20 | F. Hoffmann-La Roche Ag | 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists |
| WO2000050398A2 (en) * | 1999-02-24 | 2000-08-31 | F. Hoffmann-La Roche Ag | Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists |
| DK1394150T3 (da) * | 1999-02-24 | 2011-03-21 | Hoffmann La Roche | 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister |
| EP1103545B1 (en) * | 1999-11-29 | 2003-11-05 | F. Hoffmann-La Roche Ag | 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide |
| CN1178917C (zh) * | 2000-07-14 | 2004-12-08 | 弗·哈夫曼-拉罗切有限公司 | 作为nk1受体拮抗剂前药的4-苯基-吡啶衍生物的n-氧化物 |
| US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
-
2001
- 2001-07-09 CN CNB018128246A patent/CN1178917C/zh not_active Expired - Lifetime
- 2001-07-09 CZ CZ20030428A patent/CZ303639B6/cs not_active IP Right Cessation
- 2001-07-09 DE DE60134749T patent/DE60134749D1/de not_active Expired - Lifetime
- 2001-07-09 SI SI200130848T patent/SI1303490T1/sl unknown
- 2001-07-09 AU AU7061901A patent/AU7061901A/xx active Pending
- 2001-07-09 EP EP01949475A patent/EP1303490B1/en not_active Expired - Lifetime
- 2001-07-09 AT AT01949475T patent/ATE400556T1/de active
- 2001-07-09 PT PT01949475T patent/PT1303490E/pt unknown
- 2001-07-09 KR KR10-2003-7000476A patent/KR100501608B1/ko not_active Expired - Lifetime
- 2001-07-09 NZ NZ523273A patent/NZ523273A/en not_active IP Right Cessation
- 2001-07-09 WO PCT/EP2001/007850 patent/WO2002006236A1/en not_active Ceased
- 2001-07-09 HU HU0301311A patent/HU230316B1/hu unknown
- 2001-07-09 IL IL15383401A patent/IL153834A0/xx unknown
- 2001-07-09 MX MXPA03000366A patent/MXPA03000366A/es active IP Right Grant
- 2001-07-09 PL PL365684A patent/PL205207B1/pl unknown
- 2001-07-09 BR BRPI0112475A patent/BRPI0112475B8/pt not_active IP Right Cessation
- 2001-07-09 JP JP2002512140A patent/JP3950044B2/ja not_active Expired - Lifetime
- 2001-07-09 ES ES01949475T patent/ES2309075T3/es not_active Expired - Lifetime
- 2001-07-09 RU RU2003102612/04A patent/RU2266284C2/ru active
- 2001-07-09 ME MEP-2008-770A patent/ME01311B/me unknown
- 2001-07-09 DK DK01949475T patent/DK1303490T3/da active
- 2001-07-09 HR HR20030003A patent/HRP20030003B1/xx not_active IP Right Cessation
- 2001-07-09 RS YUP-6/03A patent/RS50932B/sr unknown
- 2001-07-09 CA CA002415890A patent/CA2415890C/en not_active Expired - Lifetime
- 2001-07-10 JO JO2001106A patent/JO2372B1/en active
- 2001-07-11 EG EG2001070771A patent/EG24968A/xx active
- 2001-07-11 PA PA20018522001A patent/PA8522001A1/es unknown
- 2001-07-12 MY MYPI20013310A patent/MY154976A/en unknown
- 2001-07-12 US US09/904,059 patent/US6593472B2/en not_active Expired - Lifetime
- 2001-07-12 GT GT200100137A patent/GT200100137A/es unknown
- 2001-07-13 AR ARP010103335A patent/AR029717A1/es active IP Right Grant
- 2001-07-13 PE PE2001000704A patent/PE20020272A1/es active IP Right Grant
- 2001-07-13 UY UY26839A patent/UY26839A1/es not_active IP Right Cessation
-
2002
- 2002-12-17 ZA ZA200210207A patent/ZA200210207B/en unknown
-
2003
- 2003-01-07 US US10/337,543 patent/US6747026B2/en not_active Expired - Lifetime
- 2003-01-07 IL IL153834A patent/IL153834A/en active IP Right Grant
- 2003-01-13 NO NO20030154A patent/NO324700B1/no not_active IP Right Cessation
- 2003-01-13 MA MA26997A patent/MA26929A1/fr unknown
- 2003-01-14 EC EC2003004431A patent/ECSP034431A/es unknown
- 2003-07-09 US US10/616,276 patent/US6897226B2/en not_active Expired - Lifetime
- 2003-08-21 US US10/645,895 patent/US6806370B2/en not_active Expired - Lifetime
-
2008
- 2008-10-07 CY CY20081101108T patent/CY1108557T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY154976A (en) | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives | |
| JO2294B1 (en) | 4 - Phenylpyridine derivatives | |
| YU8703A (sh) | Derivati 4-fenil-piridina kao antagonisti receptora neurokinina-1 | |
| JO2244B1 (en) | Vinyl and peridenyl derivatives | |
| MY140236A (en) | Diarylether compounds useful as opioid receptor antagonists | |
| NZ513370A (en) | 3-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | |
| TW200510441A (en) | Novel compounds | |
| WO2000073278A3 (en) | 5-phenyl-pyrimidine derivatives | |
| DK0979821T3 (da) | Tricykliske forbindelser | |
| JO2321B1 (en) | 4-phenyl-pyridine derivatives | |
| CA2366205A1 (en) | Biphenyl derivatives | |
| NZ515407A (en) | 4-Phenyl-pyrimidine derivatives | |
| NZ519126A (en) | Novel IL-8 receptor antagonists | |
| HRP20030610B1 (en) | Process for the preparation of mesylates of piperazine derivatives | |
| MXPA04003935A (es) | Derivados de piridina como bloqueadores del subtipo de receptores n-metil-d-aspartato. | |
| JO2307B1 (en) | Papermidine derivatives | |
| WO2002017954A1 (fr) | Medicaments contre la maladie de parkinson | |
| TH64066B (th) | โปรดรักส์ของอนุพันธ์ 4-ฟีนิล-ไพริดีน | |
| TH78827A (th) | โปรดรักส์ของอนุพันธ์ 4-ฟีนิล-ไพริดีน | |
| ECSP003363A (es) | Derivados de fenil y piridinil |